Eisai (TYO: 4523)’s Lenvima (lenvatinib) and Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) is a combination that may prove its worth for patients with multiple different cancer types.
But certain patients with advanced melanoma and metastatic colorectal cancer will not be among those to benefit after the combination failed in two Phase III trials.
The companies have announced that they are discontinuing the LEAP-003 trial evaluating the pairing for the first-line treatment of adults with unresectable or metastatic melanoma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze